



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Furthermore, comparing the means of the 2 studies, a significant decline in LGE was observed in the second CMR study (CMR I $7.4\% \pm 4.8\%$ vs CMR II $3.4\% \pm 4.2\%$; $P = 0.018$), with overall similar location and pattern of the remaining LGE. No significant difference in the volume of the left ventricle was observed.

The current study evaluated a follow-up CMR scan among patients with myocarditis after a COVID-19 vaccine. It found an improvement in LVEF and a decline in LGE, with no significant change in left ventricular volumes compared with baseline CMR scan. These findings are overall in-line with a study by Aquaro et al,² who evaluated 187 patients with "classical" viral myocarditis and found that LGE disappeared completely in 18 (10%) patients, the number of LGE segments decreased in 87 (46%), was unchanged in 58 (31%), and increased in 26 (14%). We found that the extent of LGE has decreased in all patients and disappeared completely in 1 patient. Aquaro et al² also showed that the LGE of the follow-up CMR imaging and the trend of the LGE between baseline and follow-up CMR studies was a strong prognostic marker in viral myocarditis. Thus, our findings could imply a favorable course of post-COVID-19 vaccine myocarditis, although this remains to be further proven in a larger cohort. However, a study by Mahrholdt et al⁵ in which the CMR scan was repeated 6 months after myocarditis reported a complete disappearance of LGE in 19 (27%) of 71 patients. These findings support the hypothesis that LGE in the acute setting of myocarditis does not entirely represent irreversible myocardial damage and probably results, at least partially, from the presence of edema and the inflammatory milieu increasing the volume of distribution of gadolinium and slowing its wash-out.²

We also observed a significant improvement in the left ventricular function at the follow-up CMR scan. This finding is of significance because left ventricular function at baseline and at 6 months' follow-up has been shown to be a strong predictor in patients with viral myocarditis.³ Limitations include a relatively small sample and the fact that the CMR scans were not performed in all patients and with a nonidentical (often relatively delayed) interval or different scanners resulting in potential bias.

In conclusion, follow-up CMR imaging showed a significant decline in the extent of LGE and an improvement in LVEF among patients with post-COVID-19 vaccine myocarditis, possibly supporting a relatively favorable clinical course and outcomes in these patients.

Arthur Shiyovich, MD
Ygal Plakht, PhD
Guy Witberg, MD
Yaron Aviv, MD
Gideon Shafir, MD
Ran Kornowski, MD
Ashraf Hamdan, MD*

*Department of Cardiology

Rabin Medical Center
39 Jabotinsky Street
Petah Tikva 6910203, Israel
E-mail: hamdashraf@gmail.com
<https://doi.org/10.1016/j.jcmg.2022.05.017>

© 2022 by the American College of Cardiology Foundation. Published by Elsevier.

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

REFERENCES

1. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. *N Engl J Med*. 2021;385(23):2132-2139.
2. Aquaro GD, Ghebru Habtemicael Y, Camastra G, et al. Prognostic value of repeating cardiac magnetic resonance in patients with acute myocarditis. *J Am Coll Cardiol*. 2019;74(20):2439-2448.
3. Anzini M, Merlo M, Sabbadini G, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. *Circulation*. 2013;128(22):2384-2394.
4. Shiyovich A, Witberg G, Aviv Y, et al. Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. *Eur Heart J Cardiovasc Imaging*. 2022;23(8):1075-1082. <https://doi.org/10.1093/ehjci/jeab230>
5. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. *Circulation*. 2006;114(15):1581-1590.





























Follow-Up Cardiovascular Magnetic Resonance Findings in Patients With COVID-19 Vaccination-Associated Acute Myocarditis



Several case series have described acute myocarditis developing shortly after receiving messenger ribonucleic acid (mRNA) COVID-19 vaccines.¹ Cardiac magnetic resonance (CMR) characteristics in these patients resemble those found in patients with myocarditis from other causes. However, no prior reports or studies describe the evolution of myocardial edema and late gadolinium enhancement (LGE) on serial CMR evaluation—data that may help define the natural course of the disease.

In this case series, we describe the clinical course and repeat CMR findings after 3-6 months in 9 young male patients diagnosed with acute myocarditis after receiving an mRNA-based COVID-19 vaccine. All

FIGURE 1 CMR Characteristics on Admission and on Follow-Up Among 9 Young-Adult Male Patients With Acute Myocarditis Following mRNA-Based COVID-19 Vaccination

	Admission			Follow-Up			
	CMR Parameters	LGE Images	T ₂ -Weighted Images	CMR Parameters	LGE Images	T ₂ -Weighted Images	Findings
Case 1	LVEF: 60% GLS: -15.6% GCS: -16.4% RVS: -21.3% T1: 1089 ms T2: 55 ms			LVEF: 65% GLS: -17.8% GCS: -15.6% RVS: -23.4% T1: 1040 ms T2: 45 ms			LGE: Resolving Edema: Resolving
Case 2	LVEF: 62% GLS: -17% GCS: -18% RVS: -18.2% T1: 981 ms T2: 42 ms			LVEF: 60% GLS: -13.5% GCS: -17.6% RVS: -26.1% T1: 981 ms T2: 42 ms			LGE: Resolved Edema: No change
Case 3	LVEF: 63% GLS: -12.6% GCS: -15.0% RVS: -15.7% T1: 1041 ms T2: 50 ms			LVEF: 63% GLS: -12.6% GCS: -14.8% RVS: -16.0% T1: 963 ms T2: 43 ms			LGE: Resolving Edema: Resolved
Case 4	LVEF: 65% GLS: -17.2% GCS: -16.2% RVS: -23.9% T1: 988 ms T2: NO			LVEF: 64% GLS: -17.9% GCS: -14.4% RVS: -22.9% T1: NO T2: NO			LGE: Resolving Edema: Resolved
Case 5	LVEF: 55% GLS: -15.5% GCS: -14.3% RVS: -18.6% T1: 979 ms T2: 45 ms			LVEF: 58% GLS: -14.6% GCS: -14.4% RVS: -23.4% T1: 971 ms T2: 43 ms			LGE: Resolving Edema: Resolved
Case 6	LVEF: 55% GLS: -15.5% GCS: -12.2% RVS: -19.6% T1: 1053 ms T2: 47 ms			LVEF: 54% GLS: -15.1% GCS: -12.4% RVS: -21.3% T1: 1058 ms T2: 46 ms			LGE: Resolving Edema: Resolved
Case 7	LVEF: 60% GLS: -16.5% GCS: -15.5% RVS: -14.9% T1: 932 ms T2: 44 ms			LVEF: 58% GLS: -14.3% GCS: -14.9% RVS: -15.3% T1: 954 ms T2: 44 ms			LGE: Resolving Edema: Resolved
Case 8	LVEF: 57% GLS: -14.5% GCS: -16.2% RVS: -14.7% T1: 961 ms T2: 42 ms			LVEF: 58% GLS: -13.5% GCS: -15.7% RVS: -14.4% T1: 943 ms T2: 41 ms			LGE: Resolving Edema: Resolved
Case 9	LVEF: 61% GLS: -16.5% GCS: -15.3% RVS: -22.2% T1: 984 ms T2: 46 ms			LVEF: 58% GLS: -16.8% GCS: -16.8% RVS: -27.7% T1: 969 ms T2: 42 ms			LGE: Resolving Edema: Resolved

patients developed acute myocarditis within 72 hours of receiving the second dose of COVID-19 vaccination, and they underwent initial CMR within 7 days of their hospital stay. Acute myocarditis was diagnosed based on clinical presentation (typical chest pain symptoms, electrocardiogram, and elevated cardiac biomarkers) and the presence of modified Lake Louise criteria on T₁- and/or T₂-weighted CMR images.² All CMR studies were performed on 1.5-T scanners using a standard myocarditis protocol based on guidelines from the Society for Cardiovascular Magnetic Resonance. All CMR studies were analyzed off-line using CVi42 (Circle Cardiovascular Imaging) by a level III reader. Follow-up evaluation for recurrent chest pain, hospital readmission, heart failure, and arrhythmias were obtained from outpatient cardiology clinic notes after index hospitalization discharge. The study was approved by the Institutional Review Board of the Lifespan Health System.

The mean age of the cohort was 22 years. None of the patients had a history of COVID-19 infection prior to the diagnosis of acute myocarditis. Two patients received Moderna COVID-19 vaccination and 7 patients received Pfizer COVID-19 vaccination. Over a median follow-up of 146 days, none of the patients experienced recurrent myocarditis, heart failure, or arrhythmias and none were readmitted to the hospital for any cause.

Follow-up CMR findings after a median of 94 days following initial diagnosis of acute myocarditis in these patients are shown in **Figure 1**. During the index hospitalization for acute myocarditis, subclinical myocardial dysfunction (defined by left ventricular global longitudinal strain [GLS] and/or global circumferential strain [GCS] <−17%) was present in 8 of 9 patients. On follow-up, left ventricular GLS remained mildly abnormal in 7 of 8 patients and left

ventricular GCS remained mildly abnormal in 8 of 9 patients. Similarly, right ventricular GLS was abnormal (<−23.9%) in all 9 patients at baseline, and although there was a numerical improvement in right ventricular GLS in all patients on the follow-up, only 2 of 9 patients had GLS value of >−23.9% on the follow-up. There was complete resolution of myocardial edema in 8 of 9 patients on T₂-weighted images. LGE was present initially in all cases. On follow-up, there was resolution of LGE in 1 of 9 patients and resolving but persistent LGE in 8 of 9 patients.

CMR can help determine longer-term prognosis in patients with acute myocarditis.³ The ITAMY (Italian Study in Myocarditis) registry showed that the presence of any LGE without myocardial edema compared to the absence of LGE on 6-month follow-up was associated with an increased risk of adverse cardiac events including sudden cardiac death, implantable cardioverter-defibrillator shocks, and heart failure hospitalization.⁴ In this case series, we found that most of our patients have resolving LGE without the presence of myocardial edema on follow-up. It is likely that the persistence of LGE in the absence of myocardial edema represents myocardial fibrosis. Given that no clinical events were observed in our short-term follow-up, these tissue-related imaging findings likely portend a more favorable prognosis in the short term, but a long-term follow-up is needed to determine whether such persistence of LGE is associated with future cardiac events.

Reduced left ventricular GLS and GCS in patients with acute myocarditis have been reported to be associated with worse cardiovascular outcomes.⁵ In our case series, we found persistent mild abnormalities in GLS and GCS in many patients. Such findings may portend less favorable prognosis of these patients on long-term follow-up.

FIGURE 1 Continued

Hyperintense signal suggestive of myocardial edema on T₂-weighted fat suppression (**single arrow**) and late gadolinium enhancement on T₁-weighted images (**double arrow**). All cardiac magnetic resonance (CMR) studies were performed on 1.5-T Siemens magnetic resonance imaging scanner. Global longitudinal strain (GLS) of the left ventricle was evaluated using feature tracking (CVi42) from apical long-axis views containing 4-, 3-, and 2-chamber cine views. Global circumferential strain (GCS) of the left ventricle was obtained using feature tracking on short-axis cine views. Similarly, GLS of the right ventricle was used with feature-tracking method in apical 4-chamber view. The peak strain values for GLS (negative value) and GCS (negative value) were determined from the strain curves. The reference value of left ventricular GLS and GCS was −17%, whereas the reference value of right ventricular GLS was −23.9%. T₁- and T₂-weighted mapping: myocardial native T₁ maps were obtained on 1.5-T using a breath-hold, motion-correction, electrocardiogram-triggered, modified Look-Locker inversion recovery sequence with images acquired at end diastole before and approximately 20 minutes after contrast injection in the mid-ventricular short-axis plane. T₂ mapping was performed on 1.5-T using a single-shot T₂ prepared steady-state free precession in the mid-ventricular short-axis plane at end diastole during breath-hold with motion correction. LGE = late gadolinium enhancement; LVEF = left ventricular ejection fraction; mRNA = messenger ribonucleic acid; NO = not obtained; RVS = right ventricular strain.

Limitations of this study include our relatively small patient cohort lacking any female patients. As such, our results may not be generalizable to a larger more diverse population. We did not have any Holter monitoring and exercise treadmill stress testing data on follow-up. However, the strength of this study includes robust CMR imaging techniques including T₁ and T₂ mapping, global ventricular strain reporting, and close follow-up of the patients.

This small case series suggests patients with acute myocarditis following mRNA-based COVID-19 vaccination have CMR evidence of myocardial recovery at 3-6 months but can have persistent mild abnormalities. These findings should be confirmed in a larger study cohort.

Yash R. Patel, MD, MPH*
Nishant R. Shah, MD, MPH
Kristin Lombardi, MD
Saurabh Agarwal, MD
Gregory Salber, MD
Rootu Patel, BS
Athena Poppas, MD
Michael K. Atalay, MD, PhD

*Lifespan Cardiovascular Institute
Warren Alpert Medical School at Brown University
950 Warren Avenue, Suite 201
East Providence, Rhode Island 02914, USA

E-mail: ypatel@lifespan.org
Twitter: [@YashPatel_MD](https://twitter.com/YashPatel_MD)

<https://doi.org/10.1016/j.jcmg.2022.06.009>

© 2022 by the American College of Cardiology Foundation. Published by Elsevier.

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

REFERENCES

1. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. *Circulation*. 2022;145(5):345-356.
2. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol*. 2018;72(24):3158-3176.
3. Aquaro GD, Perfetti M, Camastra G, et al. Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. *J Am Coll Cardiol*. 2017;70(16):1977-1987.
4. Aquaro GD, Ghebru Habtemicael Y, Camastra G, et al. Prognostic value of repeating cardiac magnetic resonance in patients with acute myocarditis. *J Am Coll Cardiol*. 2019;74(20):2439-2448.
5. Fischer K, Obrist SJ, Erne SA, et al. Feature tracking myocardial strain incrementally improves prognostication in myocarditis beyond traditional CMR imaging features. *J Am Coll Cardiol Img*. 2020;13(9):1891-1901.

Development and Validation of a Diagnostic Echocardiographic Mass Score in the Approach to Cardiac Masses



Cardiac masses (CMs) are a diagnostic dilemma in clinical practice and require multiple imaging techniques to assess malignancy, which is essential to guide the proper treatment.¹⁻³ Echocardiography can provide precious information and represents the first-line imaging approach to CMs, as more advanced methods may not be available at all centers. This study was planned to investigate the echocardiographic features of CMs that may suggest malignancy and build a score, the diagnostic echocardiographic mass (DEM) score, that can increase diagnostic yield.

All consecutive patients undergoing complete echocardiographic evaluations from 2004 to 2020 were enrolled. On the basis of definitive diagnosis, achieved by histologic examination or, in the case of cardiac thrombi, with radiological evidence of thrombus resolution after appropriate anticoagulant treatment, CMs were distinguished as benign or malignant and classified according to the World Health Organization's 2015 classification of tumors of the heart and pericardium.⁴ Echocardiograms were obtained using high-quality ultrasound machines (Philips iE33 or EPIQ) following the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Images were analyzed off-line by 2 expert echocardiography cardiologists with more than 10 years' experience in cardiac imaging, blinded to clinical information and CM histology. Several echocardiographic characteristics were assessed to select those able to potentially identify malignant masses. Variables maintaining statistical significance in independently predicting malignancy after logistic regression analysis were used to build a multiparametric predictive score, which was developed in a derivation sample and tested in a validation cohort. All patients were managed according to the Declaration of Helsinki and provided informed consent for the anonymous publication of scientific data. The study protocol was approved by the local ethics committee (registration number 102/2017/O/Oss).

Our final study population included 249 patients, 181 (72%) with benign CMs and 68 (28%) with malignancies, and no significant differences in terms of clinical and demographic characteristics were observed between the derivation (178 subjects [70%])